Journal Section:
Erratum

In the article entitled “Biomarker-Based Prediction of Survival and Recovery of Kidney Function in Acute Kidney Injury” by Patschan et al. [Kidney Blood Press Res 2023;48:124–134, DOI: 10.1159/000528633], the reference list is incomplete.

Below please find the missing references:

55 Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004 Sep;66(3):1115–22.

56 Yang H, Lin C, Zhuang C, Chen J, Jia Y, Shi H, et al. Serum Cystatin C as a predictor of acute kidney injury in neonates: a meta-analysis. J Pediatr (Rio J). 2022 May;98(3):230–40.

57 Çuhadar S. Serum Cystatin C as a Biomarker. In: Patel VB, editor. Biomarkers in Kidney Disease. Dordrecht: Springer Netherlands; 2015; pp 1–17.

58 Khorashadi M, Beunders R, Pickkers P, Legrand M. Proenkephalin: A New Biomarker for Glomerular Filtration Rate and Acute Kidney Injury. Nephron. 2020;144(12):655–61.

59 Beunders R, Struck J, Wu AHB, Zarbock A, Di Somma S, Mehta RL, et al. Proenkephalin (PENK) as a Novel Biomarker for Kidney Function. J Appl Lab Med. 2017 Nov;2(3):400–12.

60 Feldkamp T, Bienholz A, Kribben A. Urinary neutrophil gelatinase-associated lipocalin (NGAL) for the detection of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transpl. 2011 May;26:1456–8.

61 Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis Off J Natl Kidney Found. 2009;54:1012–24.

62 Helanova K, Spinar J, Parenica J. Diagnostic and Prognostic Utility of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Patients with Cardiovascular Diseases – Review. Kidney Blood Press Res. 2014;39(6):623–9.

63 Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C, et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PloS One. 2014;9(1):e84131.

64 Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008 Feb;73(4):465–72.

65 Hishikari K, Hikita H, Nakamura S, Nakagama S, Mizusawa M, Yamamoto T, et al. Urinary Liver-Type Fatty Acid-Binding Protein Level as a Predictive Biomarker of Acute Kidney Injury in Patients with Acute Decompensated Heart Failure. Cardiorenal Med. 2017 Oct;7(4):267–75.

66 Zou C, Wang C, Lu L. Advances in the study of subclinical AKI biomarkers. Front Physiol. 2022;13:960059.

67 Krawczeski CD, Goldstein SL, Woo JG, Wang Y, Piyaphanee N, Ma Q, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol. 2011 Nov;58(22):2301–9.

68 Meersch M, Schmidt C, Van Aken H, Martens S, Rossaint J, Singbartl K, et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PloS One. 2014;9(3):e93460.

69 Casas-Aparicio G, Alvarado-de la Barrera C, Escamilla-Illescas D, León-Rodríguez I, Del Río-Estrada PM, Calderón-Dávila N, et al. Role of Urinary Kidney Stress Biomarkers for Early Recognition of Subclinical Acute Kidney Injury in Critically Ill COVID-19 Patients. Biomolecules. 2022 Feb;12(2):275.

70 Obert LA, Elmore SA, Ennulat D, Frazier KS. A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies. Toxicol Pathol. 2021 Jul;49(5):996–1023.

71 Roscigno G, Quintavalle C, Biondi-Zoccai G, De Micco F, Frati G, Affinito A, et al. Urinary Dickkopf-3 and Contrast-Associated Kidney Damage. J Am Coll Cardiol. 2021 Jun;77(21):2667–76.

72 Ostermann M, Karsten E, Lumlertgul N. Biomarker-Based Management of AKI: Fact or Fantasy? Nephron. 2021 Aug;1–7.

© 2023 The Author(s) Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial